itx 5061
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01165359)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Hepatitis C virusINHIBITOR
Hepatitis C virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- itx 5061
- itx 5061
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01560468 | Phase 1 | Mar 1, 2012 | Icahn School of Medicine at Mount Sinai, iTherX Pharmaceuticals Inc. |
| NCT01292824 | Phase 1 | Feb 1, 2011 | National Institute for Health Research, United Kingdom, University of Birmingham |
| NCT01165359 | Phase 1 | Sep 1, 2010 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2012 |
| iTherX Pharmaceuticals Inc. | For profit | 1 | 0 | 1 | 2012 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| National Institute for Health Research, United Kingdom | Government | 1 | 0 | 1 | 2011 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2010 |
| University of Birmingham | Academic/Hospital | 1 | 1 | 1 | 2011 |
6 organizations
Page 1 / 1